100 results on '"Lévy, Christelle"'
Search Results
2. Modeling intrinsic time-lags in flaring blazars in the context of Lorentz Invariance Violation searches
3. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
4. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
5. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort
6. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
7. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres
8. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
9. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
10. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
11. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
12. Étude en vie réelle de la survie à 7 ans des patientes traitées avec trastuzumab pour un cancer du sein précoce HER2+
13. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)
14. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
15. Cancer du sein de la femme jeune. Spécificités histologiques, pronostiques : en quoi sont-elles différentes des femmes plus âgées ?
16. Facteurs décisionnels de la prise en charge des carcinomes canalaires in situ du sein avec micro-invasion
17. Complications cardiaques de la radiothérapie mammaire
18. Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials
19. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)
20. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
21. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)
22. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
23. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
24. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
25. Emotional specificities of autobiographical memory after breast cancer diagnosis
26. Cognitive change in breast cancer patients up to 2 years after diagnosis
27. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer
28. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
29. Sleep-dependent memory consolidation in breast cancer: Use of a virtual reality prospective memory task
30. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
31. Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study
32. Cognitive change in breast cancer patients up to 2 years after diagnosis.
33. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
34. One-Year Longitudinal Study of Fatigue, Cognitive Functions, and Quality of Life After Adjuvant Radiotherapy for Breast Cancer
35. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
36. Cognition and Return to Work Status 2 Years After Breast Cancer Diagnosis.
37. Additional file 1 of Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
38. sj-pdf-1-tam-10.1177_1758835920980548 – Supplemental material for Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
39. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
40. Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup
41. Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
42. Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
43. Additional file 2: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
44. Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer
45. Fragmentation du sommeil et consolidation de la mémoire prospective chez des patientes traitées pour un cancer du sein
46. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
47. GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
48. Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
49. Cognitive Changes After Adjuvant Treatment in Older Adults with Early‐Stage Breast Cancer.
50. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME MBC COHORT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.